The Sumaira Foundation’s Post

New treatment alert for #multipleSclerosis patients 🔔‼️ The FDA had approved #Ocrelizumab and Hyaluronidase ( Ocrevus Zunovo) a Twice yearly #subcutaneous injection for Relapsing MS AND primary progressive MS. That would bring the first and only twice a year 10 minutes subcutaneous injection for people living with RMS and PPMS👏 That’s a huge milestone in treatment advancement and innovation in clinical research programs to broaden the scientific understanding of MS , further reducing disability progression in RMS and PPMS and improving the treatment experience for those living with the disease. 🙏🤝 #MSInnovation #TheMSPharmacist #MultipleSclerosis #BeatMS

I and my colleagues Jon Cook from Western Health and Paul MacCartney from cohealth had our paper on direct induction onto high-dose long-acting injectable buprenorphine published today. This is the first case series to our knowledge about direct induction onto higher dose long-acting injectable buprenorphine and hope that it sparks conversations into how we can better serve and meet the needs of the patients that we see #LAIB #buprenorphine https://lnkd.in/gcp75D5M

Help educate your patients about iron deficiency anemia with our new infographic, developed in collaboration with The Association of Black Gastroenterologists and Hepatologists (ABGH), and Drs. Fola May, Shazia Siddique and Beverly Kyalwazi. This infographic provides an overview of everything patients need to know about IDA, from diagnosis to types of tests, and treatment. Access more patient education and the infographic: https://ow.ly/qWCR50TIeBS

🔥 What would you do in case of progression under #IO based treatment for a patient with advanced #HCC? Check out our first interactive patient case video from Dr Timon Vandamme & follow a patient's journey through HCC & make treatment selection and sequencing decisions Gain an understanding in the systemic treatment options for patients with advanced and intermediate HCC and know the right time to switch to 2nd line therapy Go to the interactive video here: https://ow.ly/rxAi50QpTxC #MedEd

Wound Care Advances: Cost-Effectiveness Analysis of Dehydrated Human Amnion/Chorion Membrane for Treating Venous Leg Ulcers Yields a Lower Per-Patient Cost A recent study declared DHACM to be a cost-effective alternative to non-advanced therapies for Medicare patients with a complex venous leg ulcer. Read more here: https://okt.to/WDp4An Sponsored by MIMEDX

The safety and effectiveness of a new hybrid ablation procedure to treat symptomatic Inappropriate Sinus Tachycardia (IST) is being evaluated in a new clinical trial. If your patients have symptoms of IST and are resistant or intolerant to medications, they may be eligible for the HEAL-IST Trial. Visit HEAL-IST.com to learn more. #IST #Innapropriatesinustachycardia #ClincialTrial

New from @atscommunity: Summary for Clinicians: Clinical Practice Guideline for the Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma https://lnkd.in/gVkuHMEh

🚨 𝑷𝒓𝒆𝒗𝒆𝒏𝒕𝒊𝒏𝒈 𝑪𝒐𝒏𝒕𝒓𝒂𝒔𝒕-𝑰𝒏𝒅𝒖𝒄𝒆𝒅 𝑵𝒆𝒑𝒉𝒓𝒐𝒑𝒂𝒕𝒉𝒚 🚨 💉 Recently had the opportunity to make a significant impact on patient care by intervening in the management of a patient on 𝒎𝒆𝒕𝒇𝒐𝒓𝒎𝒊𝒏 prior to undergoing a diagnostic coronary angiography with contrast dye. ☠️ As we know, patients on 𝒎𝒆𝒕𝒇𝒐𝒓𝒎𝒊𝒏, especially those with CKD, are at increased risk for lactic acidosis when exposed to IV contrast dyes. 💡 My Intervention: Upon reviewing the patient's chart, I identified the need to 𝒉𝒐𝒍𝒅 𝑴𝒆𝒕𝒇𝒐𝒓𝒎𝒊𝒏 48 𝒉𝒐𝒖𝒓𝒔 𝒃𝒆𝒇𝒐𝒓𝒆 𝒂𝒏𝒅 𝒂𝒇𝒕𝒆𝒓 𝒕𝒉𝒆 𝒑𝒓𝒐𝒄𝒆𝒅𝒖𝒓𝒆. This allowed us to minimize the risk of lactic acidosis and protect the patient’s kidney function. I also ensured the patient received adequate hydration to further reduce the risk of CIN. 🎯 Outcome: The angiography was successfully completed without complications, and the patient's renal function remained stable post-procedure. #ClinicalPharmacy #PatientSafety

 Attention all! Let’s discuss Proton Pump Inhibitors (PPIs) like Omeprazole, Pantoprazole, and Esomeprazole. These commonly treat conditions like gastroesophageal reflux disease and peptic ulcer disease. While PPIs are effective, it's essential to use them responsibly. Evidence-based medicine suggests that PPIs should be taken at the lowest dose and shortest duration for the treated condition. Long-term use has been associated with risks such as osteoporosis-related fractures, pneumonia, kidney disease, and vitamin deficiencies. However, some conditions, such as severe esophagitis, Barrett's esophagus, and acid reflux, may necessitate longer-term use of PPIs. It's always reassuring to know that you can consult your healthcare provider to determine the best treatment. As a former speech pathologist working with a laryngologist and now a patient advocate, I've seen many patients on long-term PPIs. Patients must take off PPIs for two weeks to make an accurate diagnosis with tests like a pH probe. Your voice matters—use medications wisely! #PPIs #MedicationSafety #HealthTips #Wellness #Chronicdisese#Cancer#Patientadvocacy If you want help with prevention and education about your rights, contact me here or schedule a call: https://bit.ly/3wKdINc.

The Elliot Lewis Center team presented preliminary late breaking data at CMSC comparing premedication regimens for Ocrevus. The research found patients on Ocrevus receiving a combination of oral cetirizine, dexamethasone, and famotidine had a similar frequency and severity of treatment related symptoms, but less sedation than patients receiving oral diphenhydramine, intravenous dexamethasone, and oral famotidine. The data showed this can be a safe and effective premedication regimen for patients with multiple sclerosis pursuing ocrelizumab. https://lnkd.in/eEnc4q9T